A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.
QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.
The team showed the approach could successfully monitor cytokines in infants after heart surgery, and is involved now in a larger clinical study expanding this research.
Cambridge Bioscience will be NanoInk's exclusive distributor in the UK and Ireland, NanoInk said this week.
NanoInk has tapped two distributors to sell its nanofabrication platforms in the Asia Pacific region.
Avantra Biosciences' Rapid Assay Prototyping Service, NanoInk's NanoArray Assay System
Roughly 40 percent of the funding will go toward NanoInk's BioDiscovery division, where it will be used to build out the company's sales and marketing organization and fund development of new products based on its protein nanoarray platform.
National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.
NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.
The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.
In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.